CLEVELAND, May 15, 2014 /PRNewswire-USNewswire/ -- NovelMed Therapeutics announced today positive data using its novel, humanized monoclonal antibody in two well-established models of osteoarthritis (OA), characterized by osteophyte formation and cartilage loss. Approximately one in ten people worldwide are affected by OA, with the total number of afflicted patients expected to increase from 75 ...
News Source
News Source
No comments:
Post a Comment